Gain-of-function mutations and/or mutations in the catalytic SET domain of EZH2 have been identified in non-Hodgkin lymphoma (NHL), melanoma, and other cancers [64]. The gene discussed is EZH2; the disease is non-Hodgkin lymphoma.